Regenerative Therapy with PRGF–Endoret in Orthopedics (4 tubes)

PRGF–Endoret® (Plasma Rich in Growth Factors) is a patented biomedical technology that enables the isolation and concentration of growth factors and regenerative proteins from a small volume of the patient’s own blood. The obtained concentrate activates the body’s natural tissue repair processes, promotes healing, and reduces inflammation.

The method is used in orthopedics, sports medicine, physiotherapy, and rehabilitation as part of personalized recovery programs.

Endoret® PRGF Technology

Endoret® PRGF is the first fully standardized system for obtaining autologous plasma enriched with growth factors, free of leukocytes, and with controlled activation. The preparation is made from the patient’s venous blood under sterile conditions and can be administered immediately after processing.

Advantages of the Endoret® PRGF Method

• Contains growth factors (GF) at concentrations higher than physiological levels.
• Stimulates tissue regeneration and cell proliferation.
• Forms a fibrin membrane at the injury site, providing a prolonged effect.
• Ensures gradual release of regenerative proteins.
• Absence of leukocytes reduces the risk of inflammatory reactions.
• High biological safety.
• Compatible with physiotherapy and kinesitherapy.

Role of PRGF–Endoret® in Therapy

• Maintains homeostasis of joint and connective tissues.
• Reduces inflammation.
• Stimulates cartilage cells (chondrocytes).
• Supports the synthesis of extracellular matrix components (collagen, hyaluronic acid).
• Improves local blood circulation and metabolic processes.

Indications

• Knee osteoarthritis.
• Hip osteoarthritis.
• Plantar fasciitis / heel spur.
• Patellar tendinitis (“jumper’s knee”).
• Chronic Achilles tendinopathy.
• Lateral epicondylitis (“tennis elbow”).

Contraindications

• Active oncological diseases.
• Acute infectious diseases.
• Autoimmune diseases in the acute phase.
• Severe anemia or thrombocytopenia.
• Sepsis, systemic inflammation.
• Viral hepatitis B or C, HIV infection.
• Pregnancy and lactation period.
• Severe psychoneurological disorders.

Procedure

• Venous blood collection (approximately 36 ml) in sterile tubes.
• Centrifugation and separation of blood components.
• Isolation and activation of the PRGF fraction.
• Injection of PRGF into the joint, tendon, or other affected area. The procedure may be performed under ultrasound guidance for precise localization and safety.
• Basic protocol: 1 session per week, total of 2–3 sessions depending on the indication. Further management is determined individually — from maintenance sessions every 6–12 months to repeated courses if symptoms recur.

Key Advantages

• Uses only the patient’s own blood (autologous material).
• Minimal risk of allergic reactions or rejection.
• Absence of leukocytes reduces the likelihood of inflammatory responses.
• Controlled and standardized activation of the preparation.
• High bioavailability and clinically proven safety.
• Compatible with other treatment and rehabilitation methods.

PRGF–Endoret® belongs to the category of autologous regenerative technologies. It does not replace surgical treatment in cases of severe structural joint changes but can serve as an effective component of comprehensive therapy and prevention of degenerative process progression.

Sources:
https://bti-biotechnologyinstitute.com/en/solutions/regenerative-medicine/traumatology
https://pmc.ncbi.nlm.nih.gov/articles/PMC2795806/
https://pubmed.ncbi.nlm.nih.gov/20714903/
https://www.sciencedirect.com/science/article/abs/pii/S0749806313008190
https://www.sciencedirect.com/science/article/abs/pii/S0749806312005129
https://josr-online.biomedcentral.com/articles/10.1186/s13018-020-01919-9
https://www.sciencedirect.com/science/article/pii/S2773157X23001200